Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT04595266 |
TitleChemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease | Phase
Phase 2
|
Date Added 2020-10-20 |
Location
Spain
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Anti-EGFR or Bevacizumab, FOLFOX regimen, LIVERPEARLS-Irinotecan |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04589845 |
TitleTumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Phase
Phase 2
|
Date Added 2020-10-19 |
Location
Alabama, United States
Arizona, United States California, United States Colorado, United States Delaware, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Indiana, United States Maine, United States Maryland, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States Australia Belgium Brazil Canada China Denmark France Germany Hong Kong Israel Italy Japan Korea, Republic of New Zealand Poland Portugal Puerto Rico Singapore South Africa Spain Switzerland Taiwan United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Recruiting
|
Drugs
Alectinib, Atezolizumab, Belvarafenib, Entrectinib, Idasanutlin, Inavolisib, Ipatasertib, Pralsetinib, Trastuzumab emtansine |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04591431 |
TitleThe Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | Phase
Phase 2
|
Date Added 2020-10-19 |
Location
Italy
|
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Alectinib, Atezolizumab, Brigatinib, Cobimetinib, Entrectinib, Erlotinib, everolimus, Ipatasertib, Ipilimumab, Itacitinib, Lapatinib, Nivolumab, Oncology Drugs, palbociclib, Pemigatinib, Pertuzumab, Ponatinib, Trastuzumab, Trastuzumab emtansine, Vemurafenib, Vismogedib |
Tags
MSS/ MMRp
|
| NCT ID NCT04575922 |
TitleNivolumab+Ipilimumab+RT in MSS mCRC | Phase
Phase 2
|
Date Added 2020-10-05 |
Location
Massachusetts, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Ipilimumab, Nivolumab |
Tags
MSS/ MMRp
|
| NCT ID NCT04550897 |
TitleA Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients | Phase
Phase 1
|
Date Added 2020-09-16 |
Location
Norway
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
BM7PE |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04535024 |
TitleThe Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2020-09-01 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Sintilimab |
Tags
MSS/ MMRp
|
| NCT ID NCT04483219 |
TitleTyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma. | Phase
Phase 2
|
Date Added 2020-07-23 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Unknown status
|
Drugs
TKI ± anti-PD-1 antibody |
Tags
MSS/ MMRp
|
| NCT ID NCT04444622 |
TitleImmunotherapy for Third Line Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2020-06-23 |
Location
Florida, United States
Michigan, United States New Jersey, United States New York, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT04432857 |
TitleAN0025 and Pembrolizumab Combination in Advanced Solid Tumors | Phase
Phase 1
|
Date Added 2020-06-16 |
Location
Missouri, United States
Texas, United States Utah, United States Virginia, United States France |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
AN0025, Pembrolizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT04426669 |
TitleA Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | Phase
Phase 1, Phase 2
|
Date Added 2020-06-11 |
Location
Minnesota, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Aldesleukin, Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes (TIL) |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
